Home > Healthcare > Medical Devices > Diagnostic Devices > Europe Laboratory Developed Tests Market

Europe Laboratory Developed Tests Market Trends

Report ID: GMI9341
Published Date: May 2024
Report Format: PDF

Download Free Sample

Europe Laboratory Developed Tests Market Trends

Europe is at the forefront for personalized medicine initiatives, which rely heavily on molecular diagnostics and genetic testing. LDTs play a crucial role in tailoring treatments to individual patients based on their genetic makeup and disease characteristics.

Precision medicine relies on the identification of specific biomarkers, genetic mutations, or molecular signatures associated with disease pathology. Diagnostic tests, including laboratory developed tests (LDTs), play a crucial role in identifying these biomarkers, enabling the development of targeted therapies designed to act on specific molecular targets. For example, in 2021 an initiative was launched, aimed at identifying the barriers to biomarker testing and develop policy landscape for the EU27 countries and the UK. This initiative also focused on unlocking the potential of precision medicine to improve cancer care in the region.
Additionally, next-generation sequencing (NGS), PCR-based assays, microarray analysis, and other molecular diagnostic techniques enable comprehensive profiling of genetic variations, gene expression patterns, and epigenetic modifications. These technological advancements facilitate the development of innovative diagnostic tests that support precision medicine initiatives.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Europe laboratory developed tests market size was valued at USD 2.1 billion in 2023 and is estimated to grow at 6.1% CAGR from 2024 to 2032 owing to rising demand for infectious disease testing, increasing healthcare expenditure.

The oncology segment in the Europe laboratory developed tests market held over 28% share in 2023, driven by the differentiation between benign and malignant lesions, and guide treatment decisions based on tumor histology and molecular characteristics.

Germany laboratory developed tests market size reached USD 362.7 million in revenue in 2023, attributed to leading academic institutions, research organizations, and biotechnology companies.

23andMe, Inc., Abbott, Bio-Rad Laboratories, Inc., Eurofins Scientific, F. Hoffmann-La Roche Ltd., Illumina, Inc., OPKO Health, Inc., QIAGEN, Quest Diagnostics Incorporated and SVAR Lifesciences